medigraphic.com
ISSN 1684-1824 (Electronic)

2020, Number 4

<< Back Next >>

Rev Méd Electrón 2020; 42 (4)

Implications of the intestinal microbiota in the chronic liver diseases

Arredondo BA, Arredondo RAE

Language: Spanish
References: 26
Page:
PDF size: 127.71 Kb.


ABSTRACT

Microbiota refers to the whole of microorganisms located in a normal way in different places of the bodies of pluricelular living beings, like the human body. The modifications of the axis intestine-liver have become a serious scientific problem, because in different researches researchers have found that this microbiota is related to hepatic damage depending on the cause of this hepatic lesion. To carry out a systematic review on the implication of intestinal macrobiota in liver diseases. The scientific articles published in the period 2012-2018 in different databases on line were reviewed. A total of 26 bibliographic sources were used, original articles and reviews. The authors present knowledge existent up to the moment on intestinal microbiota in patients who have liver diseases, making emphasis on hepatitis C and hepatic cirrhosis. The composition of the intestine microbiota was associated to an inflammatory and markers of hepatic fibrosis that improved with the treatment of direct action antivirals although the measures of intestinal permeability and inflammation remained inalterably. It is reported an improvement of patients carriers of viral hepatitis type C with the use direct action retrovirals, what was linked to modifications in the intestinal microbiota, and correlated to an improvement of fibrosis and liver inflammation; the advances obtained in this field open new perspectives in biomedicine.


REFERENCES

  1. Añé Kourí AL. El viroma humano. Implicaciones en la salud y enfermedad. Rev Haban Cienc Méd [Internet]. 2018 [citado 03/01/2019]; 17(3): 376-85. Disponible en: Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2018000300376&lng=es

  2. Ariza-Andraca R, García-Ronquillo M. El microbioma humano. Su papel en la salud y en algunas enfermedades. Rev Cirug y Ciruj [Internet]. 2016 [citado03/01/2018];84(1):31-5. Disponible en: Disponible en: http://www.elsevier.es/es-revista-cirugia-cirujanos-139-articulo-el-microbioma-humano-su-papel-X0009741116539900

  3. Kern T, Nielsen T. Oral Microbiota and Liver Disease. In The Human Gut-Liver-Axis in Health and Disease [Internet] 2019 [citado 07/01/2019] ; 105-120. Disponible en: Disponible en: https://link.springer.com/chapter/10.1007/978-3-319-98890-0_7

  4. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Resec [Internet]. 2009 [citado 03/01/2019]; 19:2317-23. Disponible en: Disponible en: http://genome.cshlp.org/content/19/12/2317.full.html

  5. Almaguer Mederos LE, Martínez Martínez W, Guach Hevia D. Implicaciones de la microbiota intestinal en la etiología y terapéutica de la enfermedad de Parkinson. Rev Haban Cienc Méd [Internet]. 2018 [citado 03/01/2019]; 17(1): 48-57. Disponible en: Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2018000100007&lng=es

  6. Qin N, Yang F, Li A. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59-64. Citado en PubMed;PMID:25079328.

  7. Bajaj JS, Heuman DM, Hylemon PB. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60(5):940-7. Citado en PubMed;PMID:24374295.

  8. Heidrich B, Vital M, Plumeier I, et al. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver Int. 2018; 38(1): 50-8. Citado en PubMed;PMID :28561276.

  9. Reid M, Ma Y, Scherzer R. Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus. J Infect Dis. 2018;217(8):1289-97. Citado en PubMed;PMID: 29304196.

  10. Aly AM, Adel A, El-Gendy AO, et al. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog 2016 ;8(1):42. Citado en PubMed;PMID:27625705.

  11. Inoue T, Nakayama J, Moriya K. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 2018;67(6):869-77. Citado en PubMed;PMID:29718124.

  12. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature 2014; 509(7500):357-60. Citado en PubMed;PMID:24739969.

  13. Aguilar JC. Highlights from Barcelona 2012 International Liver Congress and EASL meeting. Biotecnol Apl [Internet]. 2013 [citado 03/01/2019] ; 30(2): 145-8. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=48192

  14. Tedesco D, Thapa M, Chin C Y, et al. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease. Gastroenterology 2018 ; 154(8):2178-93. Citado en PubMed;PMID:29454797.

  15. Madsen AL, Brach T, Kern T, et al. The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease. The Human Gut-Liver-Axis in Health and Disease [Internet] 2019 [citado 07/01/2019] ; 89-104. Disponible en: Disponible en: https://www.researchgate.net/publication/328859182_The_Role_of_the_Bacterial_Microbiota_in_Alcoholic_and_Non-alcoholic_Fatty_Liver_Disease

  16. Manns MP, Buti M, Gane E. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. Citado en PubMed;PMID:28252637.

  17. Chan J, Gogela N, Zheng H. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Dig Dis Sci 2018;63(2):486-92. Citado en PubMed;PMID:28887750.

  18. Romana-Ponziani F, Putignani L, ParoniSterbini F, et al. Influence of Hepatitis C Virus Eradication With Direct-acting Antivirals on the Gut Microbiota in Patients with Cirrhosis. Aliment Pharmacol Ther 2018;48(11-12):1301- 11. Citado en PubMed;PMID: 30345704.

  19. Dolmazashvili E, Abutidze A, Chkhartishvili N, et al. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur J Gastroenterol Hepatol 2017;29(11):1223-30. Citado en PubMed;PMID: 28857900.

  20. Ciocan D, Rebours V, Voican CS, et al. Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis. Scientific reports [Internet] 2018 [citado 07/01/2019] ;8(1): 4822. Disponible en: Disponible en: https://www.nature.com/articles/s41598-018-23146-3

  21. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis 2015;33(3):338-45. Citado en PubMed;PMID: 26045267.

  22. Sacchi P, Cima S, Corbella M. Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. Dig Liver Dis 2015;47(3):218-25. Citado en PubMed;PMID:25544657.

  23. Bajaj JS, Sterling RK, Betrapally NS. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther 2016;44(6):638-43. Citado en PubMed:PMID:27417456.

  24. Kared H, Fabre T, Bedard N, et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013; 9(6)e1003422. Citado en PubMed:PMID: 23818845.

  25. Sousa GM, Oliveira IS, Andrade LJ, et al. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine. 2012;60(1):138-42. Citado en PubMed;PMID: 22748467

  26. Ponziani FR, Putignani L, Paroni Sterbini F, et al. Influence of hepatitis C virus eradication with direct‐acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018; 48(11-12): 1301-11. Citado en PubMed;PMID :30345704.




2020     |     www.medigraphic.com